Small Caliber Vessel Sclerotherapy

  • Todd V. CarteeEmail author
  • Sean T. McGuire


Sclerotherapy is the procedure of introducing a foreign body into a vein with the intent of ablating the vessel through a controlled thrombophlebitic event with resulting scar formation. Circa 460 BC, Hippocrates described a rudimentary precursor of modern sclerotherapy by inducing thrombosis through serially puncturing a vein with a slender iron rod. In the 1600s, Sigismund Eisholtz used distilled plantain water in the earliest recorded use of an injected substance to induce sclerosis. Refinement of the sclerosant material, injection technique, and the addition of foamed formulations over the past century have elevated sclerotherapy to the gold standard in the treatment of reticular and telangiectatic leg veins and an important therapeutic modality for varicose veins and saphenous reflux.


Sclerotherapy Leg veins Technique Safety Complications 


  1. 1.
    Bowes LE, Goldman MP. Sclerotherapy of reticular and telangiectatic veins of the face, hands, and chest. Dermatol Surg. 2002;28(1):46–51.PubMedGoogle Scholar
  2. 2.
    Ruckley CV, Evans CJ, Allan PL, Lee AJ, Fowkes FGR. Telangiectasia in the Edinburgh vein study: epidemiology and association with trunk varices and symptoms. Eur J Vasc Endovasc Surg. 2008;36(6):719–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Rabe E, Pannier-Fischer F, Bromen K, Schuldt K, a Stang CP, Wittenhorst M, Bock E, Weber S, Jöckel K-H. Bonner Venenstudie Der Deutschen Gesellschaft Für Phlebologie. Phlebologie. 2003;32(1):1–14.CrossRefGoogle Scholar
  4. 4.
    Ting ACW, Cheng SWK, Wu LLH, Cheung GCY. Anatomical distribution of chronic venous insufficiency in a Chinese population. Phlebology. 1999;14(1):29–32.CrossRefGoogle Scholar
  5. 5.
    Criqui MH. Chronic venous disease in an ethnically diverse population: the San Diego population study. Am J Epidemiol. 2003;158(5):448–56.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Carpentier PH, Maricq HR, Biro C, Ponçot-Makinen CO, Franco A. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France. J Vasc Surg. 2004;40(4):650–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Cornu-Thenard A, Boivin P, Baud JM, De Vincenzi I, Carpentier PH. Importance of the familial factor in varicose disease. Clinical study of 134 families. J Dermatol Surg Oncol. 1994;20(5):318–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Rabe E, Pannier F. Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German society of phlebology: original articles. Dermatol Surg. 2010;36(Suppl. 2):968–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Weiss RA, Voigts R, Howell DJ. Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg. 2011;37(6):812–5.PubMedGoogle Scholar
  10. 10.
    Palm MD, Guiha IC, Goldman MP. Foam sclerotherapy for reticular veins and nontruncal varicose veins of the legs: a retrospective review of outcomes and adverse effects. Dermatol Surg. 2010;36(s2):1026–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatol Surg. 2005;31(6):631–5. discussion 635PubMedCrossRefGoogle Scholar
  12. 12.
    Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. 2010;25(3):124–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang J, Jing Z, Schliephake DE, Otto J, Malouf GM, Gu YQ. Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China study). Phlebology. 2012;27(4):184–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Weiss RA, Weiss MA. Doppler ultrasound findings in reticular veins of the thigh subdermic lateral venous system and implications for sclerotherapy. J Dermatol Surg Oncol. 1993;19(10):947–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman MP. My sclerotherapy technique for telangiectasia and reticular veins. Dermatol Surg. 2010;36(s2):1040–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Weiss MA, Hsu JTS, Neuhaus I, Sadick NS, Duffy DM. Consensus for sclerotherapy. Dermatol Surg. 2014;40(12):1309–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Villacrosa A, Jesús PC, López JA, Estadella B, Serra-Prat M, Marinel-lo J. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg. 2006;31(1):101–7.CrossRefGoogle Scholar
  18. 18.
    Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg. 2008;35(2):238–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Hamel-Desnos C, Allaert FA. Liquid versus foam sclerotherapy. Phlebology. 2009;24(6):240–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Uncu H. Sclerotherapy: a study comparing polidocanol in foam and liquid form. Phlebology. 2010;25(1):44–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Morrison N, Neuhardt DL, Rogers CR. Incidence of side effects using carbon dioxide–oxygen foam for chemical ablation of superficial veins of the lower extremity. Eur J Vasc Endovasc Surg. 2010;40(3):407–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Peterson JD, Goldman MP. An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology. 2012;27(2):73–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D, Duffy D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg. 2004;30(3):367–72.PubMedGoogle Scholar
  24. 24.
    Noel B. Polidocanol or chromated glycerin for sclerotherapy of telangiectatic leg veins? With reply from Dr Kern et al. Dermatol Surg. 2004;30(9):1272.PubMedCrossRefGoogle Scholar
  25. 25.
    Kern P, Ramelet AA, Wutschert R. Blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatol Surg. 2011;37(11):1590–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Kern P. Sclerotherapy of telangiectasias: a painless two-step technique. Dermatol Surg. 2012;38(6):860–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Leach BC, Goldman MP. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatol Surg. 2003;29(6):612–5.PubMedGoogle Scholar
  28. 28.
    Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012;38(8):1322–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Rathbun S, Norris A, Stoner J. Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology. 2012;27:105–17.PubMedCrossRefGoogle Scholar
  30. 30.
    Sarvananthan T, Shepherd AC, Willenberg T, Davies AH. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg. 2012;55(1):243–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Kienle A, Hibst R. Optimal parameters for laser treatment of leg telangiectasia. Lasers Surg Med. 1997;20(3):346–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Mccoppin HH, Hovenic WW, Wheeland RG. Laser treatment of superficial leg veins: a review. Dermatol Surg. 2011;37(6):729–41.PubMedGoogle Scholar
  33. 33.
    Meesters AA, Pitassi LHU, Campos V. Transcutaneous laser treatment of leg veins. Lasers Med Sci. 2014;29(2):481–92.PubMedCrossRefGoogle Scholar
  34. 34.
    Parlar B, Blazek C, Cazzaniga S, Naldi L, Kloetgen HW, Borradori L, Buettiker U. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015;29(3):549–54.PubMedCrossRefGoogle Scholar
  35. 35.
    Munia MA, Wolosker N, Munia CG, Chao WS, Puech-Leão P. Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatol Surg. 2012;38(4):635–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Klein A, Buschmann M, Babilas P, Landthaler M, Bäumler W. Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd: YAG (1064 Nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. Br J Dermatol. 2013;169(2):365–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernstein EF, Noyaner-Turley A, Renton B. Treatment of spider veins of the lower extremity with a novel 532 Nm KTP laser. Lasers Surg Med. 2014;46(2):81–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Moreno-Moraga J, Smarandache A, Pascu ML, Royo J, Trelles M a. 1064 Nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology. 2013;29(10):658–66.PubMedCrossRefGoogle Scholar
  39. 39.
    Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg. 1999;25(2):105–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Nootheti PK, Cadag KM, Magpantay A, Goldman MP. Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins. Dermatol Surg. 2009;35(1):53–7.PubMedGoogle Scholar
  41. 41.
    Kern P, Ramelet AA, Wütschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg. 2007;45(6):1212–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Friedmann DP, Liolios AM, Wu DC. A randomized, double-blind, placebo-controlled study of the effect of a high-potency topical corticosteroid after sclerotherapy for reticular and telangiectatic veins. Dermatol Surg. 2015;41(10):1158–63.PubMedCrossRefGoogle Scholar
  43. 43.
    Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19–29–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Georgiev M. Postsclerotherapy hyperpigmentations: a one-year follow-up. J Dermatol Surg Oncol. 1990;16(7):608–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg. 2002;28(1):52–5.PubMedGoogle Scholar
  46. 46.
    Green D. Persistent post-sclerotherapy pigmentation due to minocycline. Three cases and a review of post-sclerotherapy pigmentation. J Cosmet Dermatol. 2002;1(4):173–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Scultetus AH, Leonel Villavicencio J, Kao TC, Gillespie DL, Ketron GD, Iafrati MD, Pikoulis E, Eifert S. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg. 2003;38:896–903.PubMedCrossRefGoogle Scholar
  48. 48.
    Tafazzoli A, Rostan EF, Goldman MP. Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation. Dermatol Surg. 2000;26(7):653–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Mlosek RK, Woźniak W, Malinowska S, Migda B, Serafin-Król M, Miłek T. The removal of post-sclerotherapy pigmentation following sclerotherapy alone or in combination with crossectomy. Eur J Vasc Endovasc Surg. 2012;43(1):100–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Moore M, Mishra V, Friedmann DP. Minocycline-induced postsclerotherapy pigmentation successfully treated with a picosecond alexandrite laser. Dermatol Surg. 2016;42(1):133–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol. 1990;16(4):327–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol. 1990;16(9):800–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Bihari I, Magyar É. Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg. 2001;27(2):133–6.PubMedGoogle Scholar
  54. 54.
    Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg. 2000;26:535–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyPenn State Hershey Medical CenterHersheyUSA

Personalised recommendations